This deals with maximizing value for resource use over a range of objectives. Allocative efficiency is concerned with which objectives to meet and to what extent some may not be met. These efficiency questions are answered by cost-utility and cost-benefit analyses.
Bootstrapping
Bootstrapping is a re-sampling procedure that employs raw computing power to estimate an empirical sampling distribution for the statistic of interest. The bootstrap method randomly selects samples from the original data set with replacements. The process is repeated a large number of times and can generate a confidence interval for cost-effectiveness analyses.
Costs/charges
Measuring the cost of a health care intervention in monetary terms is the cornerstone of all health economic analyses. The cost of a service can be defined in local currencies as the resources consumed or depleted to provide a service. These are in contrast to charges, which may be regulated or set by the market place and may not reflect the true cost of providing a service. Indeed, as charges may reflect profit or loss, the value may be falsely inflated or deflated. The measurement of costs can be divided into costs to the health service, costs to other sectors (e.g. government social service payments), and costs to the patient and family (e.g. loss of earnings by the patient or time spent caring for a relative). Costs are often classified as direct, indirect, intangible and 'other'. While these terms are commonplace, different authors may use them differently and hence careful reading is required. Definitions of the types of cost are as follows.
Direct costs
Direct costs are composed of direct health care costs and direct non-health care costs and reflect current market prices in local currencies. Direct health care costs reflect expenditures for medical products and services, such as the cost of hospital care, medications, laboratory tests and radiological procedures. Direct nonhealth care costs describe additional expenditures accrued due to health care encounters, such as the costs for transport, childcare or care of the elderly.
Indirect costs
Indirect costs reflect the cost of the loss of life, loss of livelihood, absenteeism from work, or decreased earn-ing ability. Because these costs are difficult to measure, their incorporation into economic evaluations remains controversial.
Intangible costs
Intangible costs reflect the costs of pain, suffering and other non-financial outcomes of disease. Because the measurement of these intangible costs can be difficult, they are not typically included in economic analyses, although measures of quality adjusted life years often attempt to incorporate these effects.
Other cost terms
Average cost Average cost per unit of output (i.e. total cost/total output).
Fixed cost Costs that do not vary with changes in output (e.g. fixed weekly/monthly wages, rent, initial capital outlay for equipment with long term use such as a scanner for magnetic resonance imaging).
Incremental cost
The extra cost of moving from one health care intervention to another, mutually exclusive, health care intervention.
Marginal cost The extra cost of producing an extra unit of output for a given health care intervention.
Opportunity cost In the economic sense, the cost of a service is designated by forgone opportunities. A resource used for one purpose cannot be used for another purpose. Thus, this reflects the health outcomes forgone in a programme by using resources in a competing programme.
Total cost The overall cost of producing a given output.
Variable cost Costs that vary with changes in output (e.g. disposable equipment, fee for service).
Cost analysis
An analysis that deals only with costs of a health care intervention. This is a partial economic evaluation as outcomes are not considered.
Cost-benefit analysis
it is often difficult to place a monetary value on health outcomes, such as a year of life saved, cost-benefit analysis remains controversial for the economic analysis of health care practices.
Cost-effectiveness acceptability curves
In the statistical comparison of two treatments, the acceptability curve is the plot of the probability that the incremental net benefit is positive as a function of the willingness to pay. As a method of presenting the uncertainty in cost-effectiveness results, the acceptability curves say how likely it is that the intervention is cost-effective conditional on the willingness to pay for the unit of health gain that is the subject of the analysis. In this way acceptability curves directly address the study question of whether the intervention is cost-effective, while making explicit the need to define the willingness to pay for health gain.
Cost-effectiveness analysis
Cost-effectiveness analysis measures the net cost of providing a service and also measures the outcomes obtained. Examples are cost per year of life gained or cost per case correctly diagnosed. As long as there is a common outcome of interest, such as life years saved, the costs of even completely unrelated programmes could be compared.
Cost-minimization analysis
This is a special case where there is good evidence that health outcomes are identical, e.g. life years gained, cases of cancer prevented. As the health outcome is the same the least costly intervention should be chosen. This situation is rare in clinical practice but an example would be a cost analysis of oxygen concentrators versus oxygen cylinders in patients with chronic obstructive pulmonary disease.
Cost-utility analysis
In this form of cost-effectiveness analysis, effects/ outcomes are converted into personal preferences or utilities rather than monetary terms. The results of a cost-utility analysis are typically expressed as a ratio of how much it costs per quality adjusted life year gained. For example, liver transplantation for cirrhotic patients may have a considerable effect on quality of life which is not identified if one uses only life expectancy or years of life gained from transplantation as the measure of outcome. Expressing results in a cost-utility ratio permits comparison to health care interventions with different effects.
Decision analysis
Medical decision analysis employs a set of mathematical tools based on probability theory to quantitatively compare the expected outcomes of two or more competing medical management strategies. The goal of decision analysis is to combine information in a quantitative manner to calculate a summary conclusion under conditions of uncertainty.
Decision trees
Decision trees graphically illustrate the components of a decision analysis. By convention, they are constructed from left to right, depicting the course of events related to a medical problem. There are three types of components in a decision tree: nodes (decision nodes, generally represented by squares, and chance nodes, generally represented by circles), branches (lines) and outcomes (rectangles). Decision nodes are points in the tree where a choice in alternative strategies is present. These are distinguished from chance nodes, which depict the probability of alternative events that are beyond the control of the user. Branches illustrate the paths from nodes that lead to different events. Outcomes are the final result of the decision process and may consist of clinical outcomes such as death or disease, or costs.
Disability adjusted life year (DALY)
A measure designed to assess the relative burdens of disease among different diseases and different populations worldwide. DALYs estimate the amount of healthy life lost as opposed to quality adjusted life years (QALYs), which are concerned with health gain.
Discounting
Discounting considers that costs and benefits may occur at different points in time in the treatment and evaluation of illness. For example, the costs of cancer screening will arise early on, while the benefits of screening (increased life expectancy) will occur years in the future. Today's monetary units (e.g. US dollars, pounds sterling, euros) are valued more than future monetary units as we benefit from them presently. Thus future costs can be discounted to current values. Health benefits that occur in the future should also be discounted. Discount rates ranging from 3% to 6% have been recommended.
Economic modelling
Any of the different subtypes of economic analysis may be examined through economic modelling. The essence of a model is that the critical components required to answer the research question must be included in the model, while items unlikely to significantly impact the results are excluded. Presently, economic modelling is performed through the development of computer simulations that utilize either spreadsheet programs or dedicated decision analysis software.
Incremental cost-effectiveness ratio (ICER)
This calculates the additional costs relative to the additional benefits of an alternative strategy. As the ICER compares medical interventions, it can provide useful information about the allocation of resources. A programme that is less costly and more effective than the alternative is said to be 'dominant'. A strategy that costs more and is less effective is said to be 'dominated'. Trade offs usually occur if an intervention is more effective but also costs more, or if the cost is lower but the effectiveness is also lower.
where C A and C B are the costs of interventions A and B, respectively; and E A and E B are the effectiveness of interventions A and B, respectively.
Incremental net benefit (INB)
The INB of an intervention measures the additional value of one intervention relative to an alternative intervention. The INB is defined for the comparison of two treatments, either in monetary terms or units of effectiveness (e.g. quality adjusted life years). In costbenefit analysis, the INB is simply the difference between the incremental costs between the two interventions and the incremental health outcomes. Since both are measured in monetary terms, the calculation is straightforward. In cost-effectiveness analysis, it is necessary to pre-specify a maximum willingness to pay for health gain (ceiling ratio, or lambda value) in order to translate health outcomes onto the cost scale.
Markov models
Markov models differ from decision trees in that they are recursive, or allow movement back and forth through different health states depicted in the model, whereas decision trees provide for movement through the model in only one direction. While certain advantages exist for Markov models compared to decision trees, such as more accurate accounting for the effect of time in a decision process, there are disadvantages that include the lack of 'memory' for prior events that require more sophisticated techniques to correct.
Monte Carlo simulation
This is a form of probabilistic sensitivity analysis where variables in the model, instead of taking on a single value, are represented by some mathematical distribution: for example, a mean value with a normal distribution described by a standard deviation. The simulation analyses multiple iterations by a bootstrapping method in which a different set of values are chosen randomly from the distributions specified for each of the variables.
Perspectives
The costs that are identified will depend on the viewpoint of the analysis. A health care perspective (e.g. a ministry of health) will just be concerned with identifying health care costs, whereas a societal perspective will seek to identify all costs. Viewpoints could also be the individual patient, the institution or target groups for specific services/interventions.
Quality adjusted life year (QALY)
This is a weighted composite index of two or more dimensions of health. The rating is made between 1 (perfect health) and 0 (death). As a measure of health outcome, it can capture information about gains in both quality and quantity and express these as a single measure.
Sensitivity analysis
Sensitivity analysis determines the degree to which uncertainty surrounding the costs and outcomes in the model affects the conclusions of the analysis. In sensitivity analysis, critical parameters (both costs and health outcomes) are varied over a broad range to determine if the preferred strategy changes.
Standard gamble (SG)
This is a method of measuring health utilities such as the ratings used in QALYs. Participants are requested to compare life in a given health state as a sure thing with another scenario where treatment immediately leads to either perfect health, with probability P, or death, with probability (1 À P). The value of P which results in the utility of each choice being equal is the measure of preference.
Technical efficiency (or 'X' efficiency)
This informs about the least costly method of attaining a set goal (e.g. curing dyspepsia) but it cannot give information on whether this goal was worth achieving in the first place. These efficiency questions are answered by cost-minimization and cost-effectiveness analyses.
Time trade-off (TTO)
This is a method of measuring health utilities such as the ratings used in QALYs. Participants are given an example of a specified period of life in a given (less than perfect) health state and asked how much shorter a life span they would be prepared to accept to be in perfect health. The ratio of the number of years in perfect health that is equivalent to the longer life span in an imperfect health state is the measure of preference for that health state.
Willingness to pay (WTP)
A method of measuring the resources an individual is willing to sacrifice in order to obtain a given benefit. The resource is nearly always measured in monetary terms. The benefit is usually measured in health gain but does not have to be restricted to this. This method directly values the health gain in monetary terms and is therefore particularly suited to allocative efficiency questions.
